<DOC>
	<DOCNO>NCT02798523</DOCNO>
	<brief_summary>Background : The immune system defend body bacteria harmful invader . But overact attack healthy cell mistake . The group drug call glucocorticoid ( GCs ) calm overactive immune system . But often cause negative side effect . Researchers want learn human gene respond GCs . Genes live inside cell body . They tell cell function . Researchers hope result study show develop good drug benefit GCs without side effect . Objectives : To study human gene respond glucocorticoid drug . Eligibility : Healthy adult volunteer age 18 64 . Design : Participants screen medical history physical exam . They heart test blood test . The study visit last 6 hour . Participants medical history , physical exam , 3 blood draw . Participants skin biopsy . An injection numb skin one arm . Then tool remove piece skin big pencil eraser . A GC cream apply arm . Participants get GC study drug 30 minute . It liquid drip needle place arm vein . Participants skin biopsy arm cream apply . Participants follow-up call 1 4 day later . They ask reaction health problem .</brief_summary>
	<brief_title>Genomic Responses Human Immune Non-Immune Cells Glucocorticoids</brief_title>
	<detailed_description>Glucocorticoids among frequently prescribe immunosuppressive anti-inflammatory medication worldwide . Long-term use , however , complicate serious non-immunologic side effect . Ongoing vitro experiment human primary cell laboratory suggest indeed fundamental difference genomic response immune non-immune cell glucocorticoid . These aspect drug action genomic level completely characterize . This study attempt generate list human gene non-coding RNAs differentially express regulate response glucocorticoid immune non-immune cell . These data use identify transcript , correspond protein , molecular pathway best candidate target intervention . Potential target could validate small interfere RNA ( siRNA ) library , long-term goal develop small-molecule nanoparticlefacilitated RNA interference ( RNAi ) intervention reproduce therapeutic action glucocorticoid immune cell avoid harmful side effect tissue . Healthy volunteer undergo baseline skin biopsy blood collection prior receive single intravenous dose 250 milligram methylprednisolone sodium succinate . Topical methylprednisolone apply limited area skin , contralateral site baseline skin biopsy . Blood collect 2 4 hour start drug administration . A skin biopsy obtain 4 hour drug administration , area topical methylprednisolone apply . Follow-up phone call 1 day 1 week discharge document adverse effect relate drug skin biopsy . Total length individual study participation 1-5 week . Blood sample process isolation RNA sequence 6 hematopoietic cell sub-population type ( neutrophil , B cell , CD4+ T cell , CD8+ T cell , monocyte , natural killer [ NK ] cell ) . Total RNA purify cell sub-population subject RNA sequence small-RNA sequencing . A portion baseline blood sample undergo DNA purification genome-wide genotyping . At time point , serum methylprednisolone level measure flow cytometry standard lineage marker perform . Skin biopsy subject RNA isolation RNA sequence small-RNA sequencing . A fragment skin biopsy undergo fibroblast isolation culture vitro exposure glucocorticoid generation induce pluripotent stem ( iPS ) cell .</detailed_description>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age 18 64 year 2 . Willingness sample store future research 3 . Willingness undergo genetic test EXCLUSION CRITERIA : 1 . Body Mass Index less 18 great 35 2 . Difficult peripheral venous access ( determine study staff screen ) 3 . History severe allergic reaction glucocorticoid 4 . History autoimmune autoinflammatory disease 5 . Active solid hematologic malgnancy 6 . History skin condition ( psoriasis , pemphigus , atopic dermatitis ) could affect result transcriptional analysis skin biopsy sample 7 . Diabetes mellitus 8 . Cancer chemotherapy within past 5 year 9 . Surgery within past 8 week 10 . History recent ( within past 30 day ) infection 11 . A positive test human immunodeficiency virus , hepatitis A , B C virus infection ( viral marker hepatitis screen , include HBsAg , antiHCV IgG , antiHAV IgM ) . 12 . A positive indeterminate test latent tuberculosis ( interferon gamma release assay ) 13 . History parasitic , amebic , fungal mycobacterial infection , possible latent infection 14 . Coagulation test ( PT PTT ) result outside normal range 15 . History bleed disorder 16 . Use glucocorticoid ( include topical inhale ) , nonsteroidal antiinflammatory drug ( include aspirin ) , antiepileptic drug , anticoagulant , statin , fluoxetine , diltiazem , amiodarone , clarithromycin , ketoconazole , St. John wort , within past 30 day 17 . Vaccination within past 30 day 18 . Receipt immunosuppressant immunomodulatory drug within past 30 day 19 . Pregnancy , current within past 90 day 20 . Current breastfeed 21 . Complete blood count ( CBC ) and/or acute care panel value outside NIH Department Laboratory Medicine normal reference range deem clinically significant principal investigator ( PI ) 22 . Any Electrocardiogram ( ECG ) abnormality clinically significant 23 . Any condition , investigator opinion , may put participant undue risk compromise study scientific objectives 24 . Participation clinical protocol include intervention , opinion investigator , may affect result current study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 15, 2017</verification_date>
	<keyword>Methylprednisolone</keyword>
	<keyword>Immunologic</keyword>
	<keyword>Infusion</keyword>
	<keyword>Topical</keyword>
	<keyword>Intravenous</keyword>
</DOC>